Ligence Heart
UAB Ligence · Decision date Oct 7, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for Ligence Heart, a 510(k) submitted by UAB Ligence of Kaunas, Lithuania, under number K261733. The decision date is 2026-10-07, with the application received 05/26/2026. The device falls under regulation 892.2050 with classification product code QIH, listed as Automated Radiological Image Processing Software, and the review panel and medical specialty are both Radiology. The submission is a Traditional 510(k) that was not reviewed by a third party and is not a combination product.
SESE means the device was cleared as substantially equivalent to a predicate; it is not a PMA approval. The record shows no authorized Predetermined Change Control Plan, so no predetermined modification scope is described. The public record does not state the specific components, software functions, or changed items reviewed, the predicate device, or any indications for use, and no summary or clinical evidence is included here. Those details would need to come from the underlying FDA documents rather than this database entry.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Oct 7, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261733
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- UAB Ligence
- Product code
- QIH
- Decision code
- SESE
- Decision date
- Oct 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated Radiological Image Processing Software.
- Applicant
- UAB Ligence
- Product code
- QIH
- FDA device class
- 2
FDA decision timeline
K261733 received
Application receipt date recorded by FDA.
K261733 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clever OneK260372 | Ewoosoft Co., Ltd. | 510(k) clearance | Nov 4, 2026 | FDA |
PeekMed webK262667 | Peek Health, S.A. | 510(k) clearance | Nov 4, 2026 | FDA |
CINA-Aneurysm+K262147 | AVICENNA.AI | 510(k) clearance | Oct 19, 2026 | FDA |
NeuroDRK262134 | Deep Reasoning Ai, Inc. | 510(k) clearance | Oct 7, 2026 | FDA |
QGuideCT (1.0)K260523 | Medis Medical Imaging Systems BV | 510(k) clearance | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
UAB Ligence
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Kaunas
Sources and methodology
- Original FDA record: K261733
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


